SCHEDULE 13G: Armistice Capital and Steven Boyd Disclose 7.51% Stake in Shuttle Pharmaceuticals Holdings
Beneficial Ownership Report
Armistice Capital, LLC and Steven Boyd have jointly reported a beneficial ownership of 7.51% in Shuttle Pharmaceuticals Holdings, Inc., totaling 306,057 shares of common stock as of December 31, 2024.
Summary
- Armistice Capital, LLC and Steven Boyd, collectively referred to as 'Reporting Persons,' have filed a Schedule 13G with the SEC.
- They beneficially own an aggregate of 306,057 shares of Shuttle Pharmaceuticals Holdings, Inc. common stock.
- This ownership represents 7.51% of the company's total outstanding common stock.
- The percentage is calculated based on 4,076,568 shares outstanding as of January 10, 2025, as reported in the Issuer's Form 424B3 filed on January 24, 2025.
- Armistice Capital, LLC serves as the investment manager for Armistice Capital Master Fund Ltd., which is the direct holder of these shares.
- Steven Boyd is identified as the managing member of Armistice Capital, LLC.
- The Reporting Persons certify that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer.
Sentiment
Score: 6
Explanation: The document is a factual disclosure of a beneficial ownership stake by an institutional investor. While the acquisition of a significant stake by a reputable firm like Armistice Capital could be interpreted as a positive signal of confidence in Shuttle Pharmaceuticals Holdings, Inc., the filing itself is neutral in tone and provides no performance or forward-looking statements from the issuer.
Positives
- A significant institutional investor, Armistice Capital, LLC, and its managing member, Steven Boyd, have taken a 7.51% stake in Shuttle Pharmaceuticals Holdings, Inc., which may signal confidence in the company's prospects.
Future Outlook
NA
Industry Context
This filing is a standard disclosure of a significant passive investment by an institutional fund in a publicly traded pharmaceutical company, reflecting a common practice among investment firms to report stakes exceeding 5% as required by SEC regulations.
Stakeholder Impact
- Shareholders: Existing shareholders may view the significant stake by Armistice Capital as a positive indicator of institutional interest and potential stability, though the filing explicitly states the stake is not for control influence.
Key Dates
| Date | Description |
|---|---|
| 12/31/2024 | Date of event which requires filing of this statement (beneficial ownership calculation date). |
| 01/10/2025 | Date as of which 4,076,568 shares outstanding were reported by the Issuer. |
| 01/24/2025 | Date Issuer's Form 424B3 Prospectus was filed with the SEC, reporting shares outstanding. |
| 02/14/2025 | Date of filing of this Schedule 13G statement. |
Keywords
Shuttle Pharmaceuticals Holdings Inc., Armistice Capital LLC, Steven Boyd, Schedule 13G, beneficial ownership, common stock, institutional investment, SEC filing, equity stake
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.